InVivo Therapeutics Announces Closing of Public Offering of Common Stock
November 22 2019 - 4:30PM
Business Wire
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today
announced the closing of its previously announced public offering
of 7,000,000 shares of its common stock, par value $0.00001 per
share, at a price to the public of $0.12 per share. The gross
proceeds from this offering are $840,000, before deducting the fees
and estimated offering expenses payable by InVivo Therapeutics. The
offering closed on November 22, 2019.
H.C. Wainwright & Co. acted as exclusive placement agent for
the offering.
A registration statement on Form S-3 (File No. 333-234353)
relating to the shares of common stock offered in the offering was
filed with the Securities and Exchange Commission, or the SEC, and
was declared effective by the SEC on November 14, 2019. The
offering was made only by means of a prospectus supplement and
accompanying base prospectus, which are part of the effective
registration statement. A final prospectus supplement related to
the offering was filed with the SEC and is available on the SEC’s
website at www.sec.gov. Electronic copies of the final prospectus
supplement and accompanying base prospectus may also be obtained by
contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd
Floor, New York, New York 10022, via e-mail at placements@hcwco.com
or via telephone at (646) 975-6996.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp., or the Company, is a
research and clinical-stage biomaterials and biotechnology company
with a focus on treatment of spinal cord injuries. The company was
founded in 2005 with proprietary technology co-invented by Robert
Langer, Sc.D., Professor at Massachusetts Institute of Technology,
and Joseph P. Vacanti, M.D., who then was at Boston Children’s
Hospital and who now is affiliated with Massachusetts General
Hospital. The publicly traded company is headquartered in
Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191122005466/en/
IR CONTACT: Bret Shapiro, Managing Partner CORE IR Phone:
(516) 222-2560 brets@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024